Oncology Solutions

Home Oncology Solutions

Amongst therapeutic areas, oncology unquestionably is the highest unmet need given poor survival, substantial socioeconomic burden, and financial toxicity. Advancements in oncology, with the intent to address these challenges, have resulted in improvement in patient outcomes in recent years. The rapid pace is largely attributed to the emergence of immune therapeutics, innovative modalities, and biosimilars, the increasing shift towards personalization and value-based patient care, and the integration of AI and digital technologies.

This innovation-driven growth has pushed the industry to re-evaluate and further transform the operating models to realize clinical & commercial success, address affordability and refine reimbursement strategies for long-term sustainability.

Our Oncology expert team at FutureBridge can support your oncology drug development and strategic decision-making across stages of development including tumor landscape assessments & competitive benchmarking; scientific, technical, and commercial evaluation,  translational feasibility of targets/modalities/platforms, and early indicators of success; indication prioritization based on attractiveness & white space analysis; optimal clinical development strategy & target product profile (TPP) for regulatory success; portfolio optimization; BD&L assessment and forecasting.

Current and Evolving Management of Diffuse Large B-Cell Lymphoma

Wondering how to improve your pharma R&D business for hematological malignancies such as NHL, and DLBCL, using evidence-based strategic recommendations?

Learn more in the upcoming webinar on 24 Feb 2023.

Register here

Cell Therapies in Solid Tumors: A bright future or a long shot

Life Sciences

Surmounting all the challenges, 1st cell therapy approval in solid tumors is anticipated by 2022. The spectacular success of...

Finding the Way – Strategies to Make Cell Therapies Successful in Solid Tumors

Life Sciences

Adoptive cellular therapy (ACT) has revolutionized the fight against hematological malignancies and holds significant clinical promise...

Research Report | Antibody Drug Conjugates: ASCO 2022 & Beyond

Life Sciences

FutureBridge Oncology consulting team identified 3 transformative themes at the ASCO 2022 that will impact the future.  Antibody Drug Conjugate (ADC) development leads the path Circulating DNA (ctDNA) adopts the role of a vital & versatile biomarker T Cell and...

FutureBridge | Key Highlights from ASCO 2022 – Report #2

Life SciencesParadigm Shift in R&D

For the first time since 2019, ~31,000 oncologists attended the 2022 ASCO Annual Meeting in person, recapturing the energy of the pre-Covid era. While new data that can transform patient care in oncology continued to emerge, cell therapies were among the early...

How Early Can We Cure Cancer? Circulating Tumor DNA setting new standards for early detection of Cancer

Life Sciences

FutureBridge Oncology consulting team identified 3 transformative themes at the ASCO 2022 that will impact the future.  Antibody Drug Conjugate (ADC) development leads the path Circulating DNA (ctDNA) adopts the role of a vital & versatile biomarker T Cell and...

Rare Cancers: Challenges and Roadmap for R&D Innovations

Life SciencesParadigm Shift in R&D

Drug development for Rare cancers is challenging because it is difficult to obtain relevant data from very few patients. The oncology community is increasingly facing a disproportionate fraction of the total burden of cancers, hence, requiring multi-stakeholder...

Strategic Growth Fields

A convergence of industry transformations and exponential technologies creates a pool of opportunities

Engineered Modalities/Platforms

  • Cell & gene therapy
  • Antibody Drug Conjugate(ADC)
  • Oncolytic viruses/vaccines/Simulatory cytokines
  • Targeted protein degrader

Precision Medicine

  • Personalization
  • Drug precision & Targeted therapy
  • Targeted drug delivery
  • Theragnostics

Early Detection & Screening

  • Clinical algorithms based early detection platform
  • Imaging and Radio-pharmaceutical
  • Non-invasive biopsies/NSG/Single cell/Others
  • Gene Panels


  • Immune
  • Genomic
  • Phenotypic
  • Histologic/Readiologic
Exponential Digital Technologies
  • Immuno-oncology 85% 85%
  • Synthetic Biology/Immunity 94% 94%
  • Molecularly Combinations & Adjuncts 93% 93%
  • Evolving Treatment Algo 92% 92%
  • Big Data & AI/ML 85% 85%

Business Objectives

Some examples of diverse business objectives we have worked with our clients


  • How are companies re-assessing R&D models to enhance productivity, stay competitive and maintain long-term sustainability in oncology?
  • Which game changer new innovations/technologies are essential to strengthen and optimize the portfolio in oncology?
    • Novel treatment modalities where companies are focusing on
    • Procedures and surgery devices that are most attractive for licensing precision technologies
    • Digital platforms for better patient care
  • How have companies overcome the regulatory & ethical challenges for personalized therapy programs?
  • What is the evolution in clinical trial design strategies for early market access?


  • How are the overall treatment landscape and benchmarks changing for major cancers with personalized therapies, new screening technologies, companion diagnostics, and non-invasive biopsies?
  • How clinical trials are being improved to deliver more patient-focused clinical trials in oncology?
  • What are the critical considerations to successfully navigate the CMC and regulatory landscape of modalities such as CGTs?


  • What kind of R&D and Innovation setup is required for CAR-T therapy?
  • What are the opportunities with next-generation bispecific and antibody drug conjugates?
  • What are the major learnings from the energy, sound, and navigation platforms used in aero-defense that can be adopted for increasing precision in medical devices and drug delivery in oncology?

Client's Success Stories

Life Sciences

Situational Assessment and Strategic Intelligence of Cell Therapy Landscape in Solid Tumors
Quick overview A leading pharma company wanted to take investment decisions and design a long-term development strategy for CT and therefore wanted to conduct a situational assessment and predict long-term business opportunities in the area of CT in solid tumors....

Life Sciences

Prioritization of Assets/MoAs/Targets in SCCHN based on Weak Signals Identification
Quick overview The client is a leading player in immuno-oncology and aspires to remain a leader with an increased difference/revenue gap from the followers. To achieve this client wanted to ride on existing and upcoming trends and therefore wanted to determine all the...

Our Clients

Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.


You have Successfully Subscribed!

New Feature

Login with your mobile number. Update now.